Loading organizations...
§ Private Profile · Rua dos Inventores, Madan Parque, 2825-182, Caparica, Portugal
Develops Digital Health technology for chronic cough diagnosis & management, providing insights for clinical & pharma research.
Based in Almada, Portugal, C-mo Medical Solutions develops digital health technology that analyzes patient cough characteristics to diagnose and manage chronic respiratory conditions. The company provides continuous monitoring tools that translate subtle acoustic data into actionable clinical insights for pulmonologists, pharmaceutical researchers, and clinical trial organizations while protecting patient privacy. The enterprise has raised €4.8 million in total equity funding to date, which includes a €4.1 million seed round aimed at expanding its commercial operations across European and United States markets. This financial backing was provided by notable institutional investors such as Boehringer Ingelheim Venture Fund and Portugal Ventures, while the firm has also received innovation awards from EIT Health and Altice. C-mo Medical Solutions was founded in 2019 by Diogo Tecelão, Miguel Andrade, Sara Lobo, Filipe Valadas, Alexandra Lopes, and Nuno Neuparth.
C-mo Medical Solutions has raised $9.2M across 2 funding rounds.
C-mo Medical Solutions has raised $9.2M in total across 2 funding rounds.
C-mo Medical Solutions has raised $9.2M in total across 2 funding rounds.
C-mo Medical Solutions's investors include Alexander Ehlgen, Niels Sharman, Novalis, Teresa Fiúza, Boehringer Ingelheim Venture Fund.
C-mo Medical Solutions has raised $9.2M across 2 funding rounds. Most recently, it raised $5.2M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 31, 2023 | $5.2M Seed | Alexander Ehlgen | Niels Sharman, Novalis, Teresa Fiúza | Announced |
| Aug 1, 2022 | $4M Seed | — | Boehringer Ingelheim Venture Fund | Announced |
C-mo Medical Solutions is a Lisbon-based digital health startup founded in 2019 that develops a wearable device for automated, real-time cough monitoring to aid in diagnosing and managing cough-related conditions like asthma, COPD, ILD, GERD, and bronchiectasis.[1][2][4][6] The C-mo system provides objective assessments of cough frequency and intensity through privacy-protected, ergonomic wearables that enable multi-day monitoring without disrupting daily routines, addressing the unmet need for comprehensive cough evaluation where symptoms are subjective and hard to quantify.[1][4][5] It serves patients and clinicians by generating automatic reports with insights, solving challenges in chronic cough management, and has shown growth through multiple awards (e.g., EIT Health InnoStars 2020, Altice International Innovation Award 2020) and a €4.1 million funding round.[1][3]
C-mo Medical Solutions was founded in 2019 in Lisbon, Portugal, by Diogo Tecelão (CEO), Miguel Andrade (CTO), Sara Lobo (CCO), Filipe Valadas, Alexandra Lopes, and Nuno Neuparth, blending expertise in digital health, business development, and respiratory medicine.[1][6] The idea emerged from recognizing cough's role as an early, common, yet objectively unassessed symptom in respiratory conditions, driving the need for automated recording technology.[1][4] Early traction came via a string of awards in 2019-2021, including Life Enables by Takeda, NOVA Idea Competition, and Porto Business School's i3S Health Innovation Prize, validating their innovation and attracting investors like Portugal Ventures and Novalis Biotech Incubation.[1][2]
C-mo rides the digital health and wearable diagnostics trend, capitalizing on post-pandemic demand for remote, objective respiratory monitoring amid rising chronic conditions like COPD and asthma.[1][4] Timing aligns with advances in AI-driven audio analysis and privacy-focused wearables, fueled by market forces like aging populations and unmet needs in cough management, where traditional methods lack precision.[2][4][5] By influencing clinician workflows with real-time data, C-mo contributes to the ecosystem's shift toward patient-centric, non-invasive tools, backed by incubators like Portugal Ventures and global awards.[1][2]
With €4.1 million raised, C-mo is poised to scale clinical trials, expand features (e.g., more metrics), and pursue regulatory approvals for broader adoption in respiratory care.[3][4] Trends like AI-enhanced wearables and telehealth integration will propel growth, potentially evolving C-mo into a platform influencing chronic disease management ecosystems. This positions them to transform subjective symptoms into actionable data, building on their award-winning foundation for sustained impact in digital health.[1][3]